A combination of a targeted therapy and PDL1 blockade elicited clonal expansion of leukemia-specific helper-cytotoxic CD4 T cells, which resulted in a significant survival benefit relative to treatment with the targeted therapy or PDL1 blockade alone. This evidence concerns the gene CD4 and leukemia.